Obicetrapib, a once-daily CETP inhibitor, demonstrated statistically significant LDL-C lowering of 35-40% as monotherapy and approximately 50% when combined with ezetimibe. The drug also achieved approximately 45% Lp(a) lowering versus placebo as a monotherapy. Exploratory MACE data from the BROADWAY trial showed a 21% reduction favoring obicetrapib at 1-year, with pooled BROADWAY + BROOKLYN data showing a 25% reduction. Observed beneficial effects extend beyond LDL-C to ApoB, non-HDL-C, LDL-P, HDL-C, and markers of glycemic control, renal function, and Alzheimer's disease. The company reported cash and cash equivalents of approximately $729 million at year-end 2025, securing funding for a potential US commercial launch, if approved. Obicetrapib has a potential global peak sales opportunity exceeding $8 billion, targeting over 30 million patients in the US alone who are not achieving LDL-C lowering goals. Comprehensive intellectual property protection for obicetrapib is secured until mid-2043. Positive impact on Alzheimer's biomarkers was observed, with a 2.84% benefit in p-tau217 progression in the full analysis set, increasing to 5.74% in ApoE4 carriers and 20.5% in ApoE4 homozygotes over 12 months.